SMALL CELL LUNG CARCINOMA

This study tests the drug durvalumab as a follow-up treatment for people with limited-stage small cell lung cancer whose cancer has not grown after initial chemotherapy and radiation. About 70 adults in Spain will receive durvalumab to see how safe it is and how well it controls …

This study is for people with extensive-stage small cell lung cancer whose disease got worse after first-line treatment including immunotherapy. Researchers are testing new drugs, either alone or combined with pembrolizumab, to see if they can shrink tumors or slow the cancer. Th…

This study tests a new drug called BI 764532 (obrixtamig) in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatment. The drug is designed to help the immune system attack cancer cells. The study aims to find the best…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find a safe dose and…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This early-stage study tests an experimental drug called PF-08046050 in people with advanced solid tumors that have come back or not improved with standard treatments. The drug is designed to attach to cancer cells and kill them. The main goal is to check safety and find the righ…

This early-stage study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3. It is for adults with advanced small cell lung cancer, neuroendocrine prostate cancer, or related tumors that have not responded to standard treatments. The main g…

This study tests whether giving a higher total dose of radiation, split into two treatments each day, can help people with limited-stage small cell lung cancer live longer without the cancer growing. All 300 participants will receive standard chemotherapy, and they will be random…

This study is testing whether a team of doctors from different specialties can create better treatment plans for older adults (ages 60-90) with lung cancer. Each patient will get a personalized plan based on a full health assessment. The goal is to see if this team approach helps…

This study tests a drug called onvansertib in about 37 people with small cell lung cancer that did not respond to or could not tolerate chemotherapy. Onvansertib blocks a protein that cancer cells need to repair themselves, aiming to shrink tumors. The main goal is to see how man…

This study is testing whether a precise type of radiation called stereotactic radiosurgery (SRS) can help people with small cell lung cancer that has spread to the brain. About 62 adults with up to 20 brain tumors will receive SRS, and researchers will track how many are alive af…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests a special PET scan that uses a radioactive tracer to find a protein called DLL3 on small cell lung cancer cells. The goal is to see if this imaging method is safe and can show where the cancer is in the body. About 53 people with small cell lung cancer or similar…

This study explores whether a Hospital-at-Home program can safely and effectively monitor people with small cell lung cancer after they receive the drug tarlatamab, instead of keeping them in the hospital. About 70 adults will be enrolled. The goal is to see if this approach redu…

This study is collecting blood samples and medical information from 500 adults diagnosed with lung cancer at age 45 or younger. Researchers want to understand what makes lung cancer different in younger people and find new ways to treat it. Participants will provide blood samples…

This study is collecting health information and biological samples from 730 adults newly diagnosed with lung cancer. Researchers aim to track how patients respond to treatments in real-world settings, including those often excluded from clinical trials. The goal is to better unde…